AstraZeneca PLC (AZN) PS Ratio: 4.71
Is AstraZeneca PLC’s P/S ratio high or low?
AstraZeneca PLC's P/S ratio of 4.71 is in line with its 5-year average of 4.72, around the middle of its 5-year range (3.66–5.92).
As of Friday, June 12, 2026. 0.00% below its 12-month average of 4.71.
AZN PS Ratio Chart
AZN Average PS Ratio Chart
AZN Current vs Average PS Ratio Chart
AZN PS Ratio Metrics
PS RATIO
4.71
PS RATIO AVG TTM
4.71
PS RATIO AVG 3Y
4.60
PS RATIO AVG 5Y
4.72
PS RATIO AVG 10Y
4.55
PS RATIO AVG 15Y
3.92
PS RATIO AVG 20Y
3.53
CURRENT VS TTM AVG
-0.00%
CURRENT VS 3Y AVG
+2.35%
CURRENT VS 5Y AVG
-0.16%
CURRENT VS 10Y AVG
+3.62%
CURRENT VS 15Y AVG
+20.17%
CURRENT VS 20Y AVG
+33.47%
AZN Competitors' PS Ratio
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AstraZeneca PLC (AZN) | $282.69B | 4.71 | 4.71 | 4.60 | 4.72 |
| Merck & Co., Inc. (MRK) | $298.29B | 4.55 | 3.88 | 4.31 | 4.34 |
| UnitedHealth Group Incorporated (UNH) | $368.30B | 0.82 | 0.68 | 1.07 | 1.26 |
| Amgen Inc. (AMGN) | $191.09B | 5.17 | 4.89 | 5.13 | 5.11 |
| Thermo Fisher Scientific Inc. (TMO) | $176.77B | 3.93 | 4.39 | 4.67 | 4.97 |
| AbbVie Inc. (ABBV) | $397.12B | 6.35 | 6.39 | 5.78 | 5.24 |
| Gilead Sciences, Inc. (GILD) | $156.28B | 5.31 | 5.41 | 4.32 | 3.91 |
| Abbott Laboratories (ABT) | $156.15B | 3.47 | 4.74 | 4.80 | 4.78 |
| Pfizer Inc. (PFE) | $149.18B | 2.37 | 2.32 | 2.45 | 2.86 |
| Intuitive Surgical, Inc. (ISRG) | $146.23B | 14.04 | 18.70 | 19.87 | 19.00 |
P/S vs. its own history
At 4.71, P/S is richer than usual, sitting higher than 78% of its 20-year history.
20-year low
1.38
median
3.48
20-year high
6.17
Sales Valuation
P/S Ratio
4.71
Market Cap / Annual Revenue
AstraZeneca PLC PS Ratio Formula & Definition
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
AstraZeneca PLC PS Ratio FAQ
- What is the P/S ratio for AstraZeneca PLC (AZN)?
- The P/S ratio for AZN stock is 4.71.
- Is AstraZeneca PLC's P/S ratio high or low?
- AstraZeneca PLC's P/S ratio of 4.71 is in line with its 5-year average of 4.72, around the middle of its 5-year range (3.66–5.92).
- What is the TTM average P/S ratio for AstraZeneca PLC (AZN)?
- The TTM average P/S ratio for AZN stock is 4.71.
- What is the 3Y average P/S ratio for AstraZeneca PLC (AZN)?
- The 3Y average P/S ratio for AZN stock is 4.60.
- What is the 5Y average P/S ratio for AstraZeneca PLC (AZN)?
- The 5Y average P/S ratio for AZN stock is 4.72.
- What is the 10Y average P/S ratio for AstraZeneca PLC (AZN)?
- The 10Y average P/S ratio for AZN stock is 4.55.
- What is the 15Y average P/S ratio for AstraZeneca PLC (AZN)?
- The 15Y average P/S ratio for AZN stock is 3.92.
- What is the 20Y average P/S ratio for AstraZeneca PLC (AZN)?
- The 20Y average P/S ratio for AZN stock is 3.53.
AstraZeneca PLC PS Ratio History
| DATE | PS RATIO |
|---|---|
| 2026-06-11 | 4.71 |
| 2026-06-10 | 4.62 |
| 2026-06-09 | 4.74 |
| 2026-06-08 | 4.69 |
| 2026-06-05 | 4.80 |
| 2026-06-04 | 4.70 |
| 2026-06-03 | 4.55 |
| 2026-06-02 | 4.58 |
| 2026-06-01 | 4.64 |
| 2026-05-29 | 4.80 |
| 2026-05-28 | 4.79 |
| 2026-05-27 | 4.79 |
| 2026-05-26 | 4.83 |
| 2026-05-22 | 4.83 |
| 2026-05-21 | 4.90 |
| 2026-05-20 | 4.84 |
| 2026-05-19 | 4.77 |
| 2026-05-18 | 4.75 |
| 2026-05-15 | 4.69 |
| 2026-05-14 | 4.78 |
| 2026-05-13 | 4.85 |
| 2026-05-12 | 4.77 |
| 2026-05-11 | 4.70 |
| 2026-05-08 | 4.72 |
| 2026-05-07 | 4.71 |
| 2026-05-06 | 4.78 |
| 2026-05-05 | 4.68 |
| 2026-05-04 | 4.74 |
| 2026-05-01 | 4.77 |
| 2026-04-30 | 4.84 |
| 2026-04-29 | 4.78 |
| 2026-04-28 | 4.96 |
| 2026-04-27 | 4.99 |
| 2026-04-24 | 5.05 |
| 2026-04-23 | 5.11 |
| 2026-04-22 | 5.18 |
| 2026-04-21 | 5.21 |
| 2026-04-20 | 5.34 |
| 2026-04-17 | 5.45 |
| 2026-04-16 | 5.33 |
| 2026-04-15 | 5.35 |
| 2026-04-14 | 5.43 |
| 2026-04-13 | 5.38 |
| 2026-04-10 | 5.43 |
| 2026-04-09 | 5.45 |
| 2026-04-08 | 5.43 |
| 2026-04-07 | 5.34 |
| 2026-04-06 | 5.39 |
| 2026-04-02 | 5.41 |
| 2026-04-01 | 5.34 |
| 2026-03-31 | 5.24 |
| 2026-03-30 | 5.16 |
| 2026-03-27 | 5.01 |
| 2026-03-26 | 4.88 |
| 2026-03-25 | 4.98 |
| 2026-03-24 | 4.94 |
| 2026-03-23 | 4.89 |
| 2026-03-20 | 4.88 |
| 2026-03-19 | 5.02 |
| 2026-03-18 | 5.01 |
| 2026-03-17 | 5.09 |
| 2026-03-16 | 5.11 |
| 2026-03-13 | 5.05 |
| 2026-03-12 | 5.12 |
| 2026-03-11 | 5.14 |
| 2026-03-10 | 5.19 |
| 2026-03-09 | 5.18 |
| 2026-03-06 | 5.16 |
| 2026-03-05 | 5.25 |
| 2026-03-04 | 5.36 |
| 2026-03-03 | 5.37 |
| 2026-03-02 | 5.42 |
| 2026-02-27 | 5.54 |
| 2026-02-26 | 5.42 |
| 2026-02-25 | 5.47 |
| 2026-02-24 | 5.49 |
| 2026-02-23 | 5.50 |
| 2026-02-20 | 5.48 |
| 2026-02-19 | 5.60 |
| 2026-02-18 | 5.60 |
| 2026-02-17 | 5.63 |
| 2026-02-13 | 5.52 |
| 2026-02-12 | 5.49 |
| 2026-02-11 | 5.50 |
| 2026-02-10 | 5.19 |
| 2026-02-09 | 5.05 |
| 2026-02-06 | 5.18 |
| 2026-02-05 | 5.03 |
| 2026-02-04 | 5.03 |
| 2026-02-03 | 4.95 |
| 2026-02-02 | 5.06 |
| 2026-01-30 | 5.02 |
| 2026-01-29 | 4.92 |
| 2026-01-28 | 5.04 |
| 2026-01-27 | 5.05 |
| 2026-01-26 | 4.81 |
| 2026-01-23 | 4.77 |
| 2026-01-22 | 4.82 |
| 2026-01-21 | 4.70 |
| 2026-01-20 | 4.92 |
| 2026-01-16 | 5.13 |
| 2026-01-15 | 5.07 |
| 2026-01-14 | 5.11 |
| 2026-01-13 | 5.07 |
| 2026-01-12 | 4.98 |
| 2026-01-09 | 5.13 |
| 2026-01-08 | 5.06 |
| 2026-01-07 | 5.12 |
| 2026-01-06 | 5.12 |
| 2026-01-05 | 4.81 |
| 2026-01-02 | 4.91 |
| 2025-12-31 | 4.71 |
| 2025-12-30 | 4.86 |
| 2025-12-29 | 5.02 |
| 2025-12-26 | 4.87 |
| 2025-12-24 | 5.01 |
| 2025-12-23 | 4.91 |
| 2025-12-22 | 4.85 |
| 2025-12-19 | 4.87 |
| 2025-12-18 | 4.85 |
| 2025-12-17 | 4.96 |
| 2025-12-16 | 4.91 |
| 2025-12-15 | 4.94 |
| 2025-12-12 | 4.82 |
| 2025-12-11 | 4.85 |
| 2025-12-10 | 4.89 |
| 2025-12-09 | 4.81 |
| 2025-12-08 | 4.86 |
| 2025-12-05 | 4.82 |
| 2025-12-04 | 4.84 |
| 2025-12-03 | 4.92 |
| 2025-12-02 | 4.81 |
| 2025-12-01 | 4.84 |
| 2025-11-28 | 4.93 |
| 2025-11-26 | 5.06 |
| 2025-11-25 | 5.04 |
| 2025-11-24 | 4.91 |
| 2025-11-21 | 4.90 |
| 2025-11-20 | 4.78 |
| 2025-11-19 | 4.83 |
| 2025-11-18 | 4.70 |
| 2025-11-17 | 4.71 |
| 2025-11-14 | 4.69 |
| 2025-11-13 | 4.77 |
| 2025-11-12 | 4.72 |
| 2025-11-11 | 4.70 |
| 2025-11-10 | 4.70 |
| 2025-11-07 | 4.46 |
| 2025-11-06 | 4.54 |
| 2025-11-05 | 4.48 |
| 2025-11-04 | 4.56 |
| 2025-11-03 | 4.47 |
| 2025-10-31 | 4.55 |
| 2025-10-30 | 4.54 |
| 2025-10-29 | 4.52 |
| 2025-10-28 | 4.57 |
| 2025-10-27 | 4.52 |
| 2025-10-24 | 4.52 |
| 2025-10-23 | 4.64 |
| 2025-10-22 | 4.60 |
| 2025-10-21 | 4.64 |
| 2025-10-20 | 4.61 |
| 2025-10-17 | 4.71 |
| 2025-10-16 | 4.67 |
| 2025-10-15 | 4.64 |
| 2025-10-14 | 4.67 |
| 2025-10-13 | 4.66 |
| 2025-10-10 | 4.67 |
| 2025-10-09 | 4.69 |
| 2025-10-08 | 4.75 |
| 2025-10-07 | 4.69 |
| 2025-10-06 | 4.75 |
| 2025-10-03 | 4.70 |
| 2025-10-02 | 4.54 |
| 2025-10-01 | 4.49 |
| 2025-09-30 | 4.13 |
| 2025-09-29 | 4.03 |
| 2025-09-26 | 4.03 |
| 2025-09-25 | 4.13 |
| 2025-09-24 | 4.11 |
| 2025-09-23 | 4.16 |
| 2025-09-22 | 4.33 |
| 2025-09-19 | 4.26 |
| 2025-09-18 | 4.23 |
| 2025-09-17 | 4.31 |
| 2025-09-16 | 4.22 |
| 2025-09-15 | 4.27 |
| 2025-09-12 | 4.40 |
| 2025-09-11 | 4.47 |
| 2025-09-10 | 4.42 |
| 2025-09-09 | 4.43 |
| 2025-09-08 | 4.50 |
| 2025-09-05 | 4.54 |
| 2025-09-04 | 4.47 |
| 2025-09-03 | 4.48 |
| 2025-09-02 | 4.43 |
| 2025-08-29 | 4.45 |
| 2025-08-28 | 4.37 |
| 2025-08-27 | 4.43 |
| 2025-08-26 | 4.42 |
| 2025-08-25 | 4.50 |
| 2025-08-22 | 4.33 |
| 2025-08-21 | 4.44 |
| 2025-08-20 | 4.35 |
| 2025-08-19 | 4.39 |
| 2025-08-18 | 4.43 |
| 2025-08-15 | 4.29 |
| 2025-08-14 | 4.30 |
| 2025-08-13 | 4.26 |
| 2025-08-12 | 4.09 |
| 2025-08-11 | 4.03 |
| 2025-08-08 | 3.91 |
| 2025-08-07 | 4.06 |
| 2025-08-06 | 4.10 |
| 2025-08-05 | 4.15 |
| 2025-08-04 | 4.15 |
| 2025-08-01 | 4.07 |
| 2025-07-31 | 4.07 |
| 2025-07-30 | 4.30 |
| 2025-07-29 | 4.15 |
| 2025-07-28 | 4.09 |
| 2025-07-25 | 4.13 |
| 2025-07-24 | 4.17 |
| 2025-07-23 | 4.18 |
| 2025-07-22 | 4.03 |
| 2025-07-21 | 3.97 |
| 2025-07-18 | 3.91 |
| 2025-07-17 | 3.93 |
| 2025-07-16 | 4.03 |
| 2025-07-15 | 3.99 |
| 2025-07-14 | 4.06 |
| 2025-07-11 | 3.98 |
| 2025-07-10 | 4.08 |
| 2025-07-09 | 4.01 |
| 2025-07-08 | 3.98 |
| 2025-07-07 | 4.05 |
| 2025-07-03 | 3.99 |
| 2025-07-02 | 4.08 |
| 2025-07-01 | 3.97 |
| 2025-06-30 | 3.97 |
| 2025-06-27 | 3.92 |
| 2025-06-26 | 3.97 |
| 2025-06-25 | 4.15 |
| 2025-06-24 | 4.01 |
| 2025-06-23 | 4.03 |
| 2025-06-20 | 3.97 |
| 2025-06-18 | 4.08 |
| 2025-06-17 | 4.00 |
| 2025-06-16 | 4.21 |
| 2025-06-13 | 4.20 |
| 2025-06-12 | 4.26 |
| 2025-06-11 | 4.21 |
| 2025-06-10 | 4.16 |
| 2025-06-09 | 4.16 |
| 2025-06-06 | 4.10 |
| 2025-06-05 | 4.05 |
| 2025-06-04 | 4.13 |
| 2025-06-03 | 4.05 |
| 2025-06-02 | 4.05 |
| 2025-05-30 | 4.02 |
Showing the most recent 260 of 5,032 data points. The chart above shows the full history.
Related Metrics
About AstraZeneca PLC
AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Pascal Claude Roland Soriot